New triple therapy aims to slow advanced lung cancer

NCT ID NCT06536868

Recruiting now Disease control Sponsor: Second Hospital of Shanxi Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment for people with extensive-stage small-cell lung cancer, a type of lung cancer that has spread. The treatment combines the drug tislelizumab with chemotherapy and radiation to the chest. The goal is to see if this combination can help control the cancer longer. About 40 adults aged 18 to 80 who have not had prior treatment for this stage will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Contacts and locations

Locations

Jincheng General Hospital
RECRUITING

Jincheng, Shanxi, 048000, China
Jinzhong third people's hospital
RECRUITING

Jinzhong, Shanxi, 032000, China
Second Hospital of Shanxi Medical University
RECRUITING

Taiyuan, Shanxi, 030000, China
Shanxi Bethune Hospital
RECRUITING

Taiyuan, Shanxi, 030000, China
Shanxi Hospital of Traditional Chinese Medicine
RECRUITING

Taiyuan, Shanxi, 030000, China
TISCO General Hospital
RECRUITING

Taiyuan, Shanxi, 030000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.